CD8A and breast carcinoma: Thus, the significant increase of infiltration of immune cells, particularly CD4+ and CD8+ T cells induced by TheraVacPlus, suggests added value with respect to immunotherapeutic efficacy of R848 in 4T1 breast cancer.